Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Labs Had Effective "Co-Sponsor" for Ceftaroline Review

This article was originally published in RPM Report

Executive Summary

FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data.
Advertisement

Related Content

Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
Ceftaroline: A Success for Biomarker Development
Antibiotic Early Endpoints: FDA Looking At Patient Observations
Antibiotic Development Incentive Menu: Options Getting Longer
Antibiotic Development Incentive Menu: Options Getting Longer
Antibiotic Susceptibilty Re-labeling Increases FDA Susceptibility To New Political Challenges!
Antibiotic Assistance

Topics

Advertisement
UsernamePublicRestriction

Register

PS080746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel